We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MRAM:NASDAQEverspin Technologies, Inc. Analysis

Data as of 2026-05-29 - not real-time

$27.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Everspin Technologies has just announced a sizable defense contract that has sparked a sharp rally, pushing the stock well above recent support levels and into a bullish price trend. Revenue growth remains modest but positive, and the company’s gross margins are healthy, yet operating results are still loss‑making with weak cash conversion. Technical indicators show a strong upward bias with short‑term moving averages well above longer‑term averages, while the RSI hovers around the midpoint, suggesting limited over‑bought pressure. However, the MACD histogram has turned negative and trading volume is on a downtrend, hinting at possible short‑term weakness.
Valuation metrics are markedly stretched: the price‑to‑earnings multiple dwarfs the industry average and the discounted cash‑flow model implies a fair value far below the current market price. The stock’s beta and recent volatility are exceptionally high, amplifying downside risk despite the “extreme greed” sentiment reading. In this context, the upside appears limited while the downside risk remains pronounced, especially if the recent price surge cannot be sustained.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Recent price rally may be exhausted
  • Negative MACD histogram
  • Decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Defense contract provides multi‑year revenue visibility
  • Fundamentals still weak with negative cash flow
  • Valuation remains far above fair value

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential for niche market leadership in MRAM technology
  • High beta and volatility could magnify losses
  • Lack of dividend and limited earnings growth

Key Metrics & Analysis

Financial Health

Revenue Growth13.20%
Profit Margin0.50%
P/E Ratio2700.0
ROE0.43%
ROA-5.58%
Debt/Equity4.27
P/B Ratio9.0
Op. Cash Flow$9.1M
Free Cash Flow$-8331500
Industry P/E41.6

Technical Analysis

TrendBullish
RSI49.9
Support$17.48
Resistance$51.50
MA 20$30.70
MA 50$18.89
MA 200$11.92
MACDBearish
VolumeDecreasing
Fear & Greed Index93.8

Valuation

Fair Value$7.81
Target Price$18.00
Upside/Downside-33.33%
GradeOvervalued
TypeBlend

Risk Assessment

Beta3.53
Volatility200.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.